Skip to content
Home/Companies/Biotech/VascVersa
VascVersa

VascVersa

Biotech·United Kingdom·Active·5yr hold
Entry
2021
Hold
5yr
Status
Active

Who owns VascVersa?

VascVersa is currently owned by Clarendon Fund Managers through Co-Fund NI (2012 vintage), since 2021.

Hand-verified · updated 2026-07-17

Clarendon Fund Managers
Investor
Clarendon Fund Managers
Co-Fund NI · 2012 · VC

Key facts

HQUnited Kingdom
SectorBiotech
StatusActive
Websitewww.vascversa.com

More from Co-Fund NI

Other portfolio companies in the same fund.

GenoME Diagnostics
GenoME Diagnostics
Active
HealthcareUK· 2023
Kinsetsu
Active
SoftwareUK· 2023
Amply
Amply
Active
BiotechUnited Kingdom· 2022
Angoka
Angoka
Active
CybersecurityUnited Kingdom· 2022
Aramune Technologies
Aramune Technologies
Active
BiotechUnited Kingdom· 2022
CV6 Therapeutics
CV6 Therapeutics
Active
HealthcareUK· 2022

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Antiverse
Antiverse
Active
Future Planet CapitalUK
CellCentric
CellCentric
Active
Future Planet CapitalUK
Crescendo Biologics
Crescendo Biologics
Active
Future Planet CapitalUK
Cytox Group
Exited 2024
Future Planet CapitalUK
GenSight Biologics
GenSight Biologics
Active
Sofinnova PartnersFrance
Healx
Healx
Active
Amadeus Capital PartnersUK
Track VascVersa

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Get the full record on VascVersa.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyers and MOIC on realized deals (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue